Company Overview and News
FRANKFURT: Germany's drug assessment body has criticized a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.
FRANKFURT, Jan 15 (Reuters) - Germany’s drug assessment body has criticised a lack of data directly comparing drugs in a promising new class of cancer immunotherapy, saying physicians could be overwhelmed or misled by the available information.
NASDAQ:CKPT Checkpoint Therapeutics Inc. ( CKPT) holds a portfolio of targeted anti-cancer and immuno-oncology agents which it is developing for both mono- and combination therapies in solid tumors. The company currently has six cancer compounds in preclinical and clinical stage development that focus on specific cellular markers and cancer signaling pathways. In a previous article, we discussed the company’s third generation EGFR inhibitor, CK-101, including the drug’s significant potential market opportunity as a single-agent therapy for non-small cell lung cancer patients, as well as how it may realize synergies in combination with CK-301, an anti-PD-L1 checkpoint inhibitor antibody also under development by the company. (1-0)
ZURICH (Reuters) - Nestle (NESN.S) is the frontrunner to buy Merck KGaA’s (MRCG.DE) consumer health unit that could fetch as much as $5 billion, financial news service Bloomberg said on Wednesday, quoting unidentified sources familiar with the matter.
FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company’s finance chief as saying. (19-0)
Jewelry store Claire's said Thursday that lab results certified its products as asbestos-free, following allegations of the toxic substance in its products last month.
Pfizer expects robust revenue growth for its biosimilars as well as emerging markets portfolio in 2017. (14-0)
If I look back at my investing mistakes (and I've made several), it's clear that I have more regrets about selling stocks than buying them. That's why I keep a portfolio of 40 dividend growth stocks that I never plan to sell. It gives me a way to remove my emotions from my investments and, maybe, if I'm lucky, to hold on to something special. (46-0)
Key announcements this week include the FDA approval of an eye disease drug as well as a diabetes treatment and label expansions for existing products. Regulatory and pipeline updates were also provided by companies like AstraZeneca (AZN - Free Report) and Johnson & Johnson (JNJ - Free Report) . Recap of the Week’s Most Important Stories Aerie’s Rhopressa Gains FDA Approval: Aerie Pharmaceuticals (AERI - Free Report) got a boost with the earlier-than-expected FDA approval of Rhopressa for the lowering of elevated intraocular pressure (“IOP”) in patients with open-angle glaucoma or ocular hypertension. (162-0)
The recent FDA approval of Exelixis, Inc.’s (EXEL - Free Report) Cabometyx for the treatment previously untreated advanced renal cell carcinoma has put the spotlight in this space. (56-1)
Today we will discuss an article on Valeant (VRX) by Michael Wiggins De Oliveira, titled, “Valeant: I Was Serious – The Clock Is Ticking.” (334-4)
LONDON/FRANKFURT (Reuters) - U.S. drugmaker Perrigo (PRGO.N) has decided to enter the fray for Merck KgaA’s (MRCG.DE) consumer health unit, sources told Reuters on Thursday, and is preparing an indicative offer for the $4.7 billion business ahead of the Dec. 15 deadline.
FRANKFURT (Reuters) - Germany’s Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales, after regulators’ concerns about side effects scuttled its ambitions almost seven years ago.
Verastem is analyzed after its presentation at the.American Society of Hematology conference in Atlanta this week. (41-0)
Geneva: Nestle SA chief executive officer Mark Schneider made his biggest acquisition yet, agreeing to buy Canadian dietary supplements maker Atrium Innovations for $2.3 billion in a bid for growth beyond stagnating mainstream food brands. (24-0)
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton